Research Insights

Cell and Advanced Therapies Supply Chain Management Market, 2019-2030: Focus on Technological Solutions (Cell Orchestration Platforms, Enterprise Manufacturing Systems, Inventory Management Systems, Laboratory Information Management Systems, Logistics Management Systems, Patient Management Systems, Quality Management Systems, Tracking & Tracing Systems, and Other Software)

Advanced therapy medicinal products, such as cell and gene therapies, have revolutionized healthcare practices. The introduction of such treatment options has led to a paradigm shift in drug development, production and consumption. Moreover, such therapies have actually enabled healthcare providers to treat several difficult-to-treat clinical conditions. In the past two decades, more than 30 such therapy products have been approved; recent approvals include Zolgensma® (2019), RECELL® System (2018), AmnioFix® (2018), EpiFix® (2018), EpiBurn® (2018), Alofisel® (2018), LUXTURNA™ (2017), Yescarta® (2017), and Kymriah® (2017). Further, according to a report published by The Alliance for Regenerative Medicine in 2019, more than 1,000 clinical trials are being conducted across the globe by over 900 companies. In 2018, around USD 13 billion was invested in this domain, representing a 73% increase in capital investments in this domain, compared to the previous year.  It is worth highlighting that, based on an assessment of the current pipeline of cell therapies and the historical clinical success of such products, it is likely that around 10-20 advanced therapies are approved by the US FDA each year, till 2025.  The commercial success of cell and advanced therapies is not only tied to whether they are capable of offering the desired therapeutic benefits, but also on whether the developers are able to effectively address all supply chain requirements. The advanced therapy medicinal products supply chain is relatively more complex compared to the conventional pharmaceutical supply chain. As a result, there are a number of risks, such as possible operational inefficiencies, capacity scheduling concerns, process delays leading to capital losses, and deliverable tracking-related issues, which need to be taken into consideration by therapy developers. This has generated a need for bespoke technological solutions, which can be integrated into existing processes to enable the engaged stakeholders to oversee and manage the various aspects of the cell and advanced therapies supply chain, in compliance to global regulatory standards. Over the years, several innovative, software-enabled systems, offering supply chain orchestration and needle-to-needle traceability, have been developed. The market has also recently witnessed the establishment of numerous partnerships, most of which are agreements between therapy developers and software solutions providers. Further, given the growing demand for cost-effective personalized medicinal products, and a myriad of other benefits of implementing such software solutions, the niche market is poised to grow significantly in the foreseen future. Scope of the Report The ‘Cell and Advanced Therapies Supply Chain Management Market: Focus on Technological Solutions, 2019-2030’ report features an extensive study of the growing supply chain management software solutions market. The focus of this study is on software systems, including cell orchestration platforms (COP), enterprise manufacturing systems (EMS), inventory management systems (IMS), laboratory information management systems (LIMS), logistics management systems (LMS), patient management systems (PMS), quality management systems (QMS), tracking and tracing software (TTS), and other such platforms that are being used to improve / optimize various supply chain-related processes of cell and advanced therapies. Amongst other elements, the report features: A detailed assessment of the current market landscape, featuring a comprehensive list of over 160 technological platforms that are being used to manage the cell and advanced therapies supply chain, along with information on the different types of software systems (COP, EMS, IMS, LIMS, LMS, PMS, QMS, TTS, and others), their key specifications and benefits (chain of identity and custody, compatibility and integration, data management and analytics, regulatory compliance, reliability and security, scalability, software-as-a-service, traceability, user-friendliness, workflow management, and others), affiliated modes of deployment (cloud and on-premises), scale of management (small enterprise, mid-size enterprise and large enterprise), end users (biobanks, cell therapy labs, hospitals, research institutes, commercial organizations, and others), applications (ordering and scheduling, sample collection, manufacturing, logistics, and patient verification and treatment follow-up), regulatory certifications / accreditations (21 CFR Part 11, CLIA, FACT-JACIE, GAMP 5, GDPR, HIPAA, and others), and key support services offered (customization, installation / implementation, maintenance, training / technical support, upgradation, validation and testing, and others). An insightful company competitiveness analysis, taking into consideration the supplier power (based on their employee base and years of experience in the industry) and portfolio-related parameters, such as number of software solutions offered, affiliated modes of deployment, scale of management, end users, applications, regulatory certifications / accreditations, support services offered, and key platform specifications and benefits. Comprehensive profiles of industry players that are currently offering software solutions for supply chain management, featuring an overview of the company, its financial information (if available), and a detailed description of its software system(s). Each profile also includes a list of recent developments, highlighting the key achievements, partnership activity, and the likely strategies that may be adopted by these players to fuel growth, in the foreseen future. A detailed review of the cell and advanced therapies supply chain, offering insights on the processes associated with various stages, such as donor eligibility assessment, sample collection, manufacturing, logistics, and patient verification and treatment follow-up, along with information on cost requirements and existing opportunities for improvement in the supply chain management practices. A qualitative assessment of the current and long-term needs of different stakeholders (patients, healthcare providers, collection centers, manufacturers, logistics service providers and regulators / payers) involved in the cell and advanced therapies supply chain, featuring a summary of the diverse needs and areas of concern, along with our opinion (based on past and prevalent trends) on how the industry is preparing to address such issues.  An analysis of the investments made at various stages of development, such as seed financing, venture capital financing, debt financing, grants, capital raised from IPOs and subsequent offerings received by companies that are engaged in this field. An analysis of the partnerships that have been established in the domain, in the period between 2014 and Q3 2019, covering software licensing agreements, mergers and acquisitions, product development agreements, product integration agreements, distribution agreements, asset purchase agreements, and other relevant deals. A detailed analysis of the platform utilization use cases where aforementioned software systems were leveraged by various stakeholders in the domain, in the period between 2014 and Q3 2019, highlighting the ways in which companies have implemented such systems to improve / optimize various supply chain-related processes of cell and advanced therapies. An in-depth analysis of the cost saving potential across various processes of the cell and advanced therapies supply chain that can be brought about by the implementation of bespoke and integrated technological solutions / software systems. A case study on COPs, featuring insights on their key functions and implementation strategies, while also considering their strategic position and connectivity with other adjacent systems within the cell and advanced therapies supply chain. In addition, it provides a brief discussion on the growing popularity of COPs on the social media platform, Twitter. One of the key objectives of the report was to understand the primary growth drivers and estimate the future size of the supply chain management software solutions market. Based on multiple parameters, such as number of cell and advanced therapies under development, expected pricing, likely adoption rates, and potential cost saving opportunities from different software systems, we have developed informed estimates of the evolution of the market, over the period 2019-2030. In addition, we have provided the likely distribution of the current and forecasted opportunity across [A] different software systems (COP, EMS, IMS, LIMS, LMS, PMS, QMS, and TTS), [B] applications (donor eligibility assessment, sample collection, manufacturing, logistics, and patient verification and treatment follow-up), [C] modes of deployment (cloud and on-premises), [D] end users (biobanks, cell therapy labs, hospitals, research institutes, and commercial organizations), and [E] key geographical regions (North America, Europe and Asia-Pacific). In order to account for the uncertainties associated with some of the key parameters and to add robustness to our model, we have provided three market forecast scenarios portraying the conservative, base and optimistic tracks of the industry’s evolution. The opinions and insights presented in this study were influenced by discussions conducted with several stakeholders in this domain. The report features detailed transcripts of interviews held with the following individuals:  Bryan Poltilove (Vice President and General Manager, Thermo Fisher Scientific) Jacqueline Barry (Chief Clinical Officer, Cell and Gene Therapy Catapult) Jill Maddux (Director, Cell and Gene Therapy Product Strategy, McKesson) and Divya Iyer (Senior Director, Corporate Strategy and Business Development, McKesson) Martin Lamb (Chief Business Officer, TrakCel) All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

...read more
Automotive Lithium-ion Battery Market: Global Opportunity and Trend Analysis, 2019-2030

The global automotive lithium-ion battery market was $17.4 billion in 2019 and is expected to reach $95.3 billion by 2030, growing at an estimated CAGR of 17.1 % during the forecast period. Lithium-ion batteries are advanced rechargeable batteries that are used in portable consumer electronic products and in electric vehicles, such as e-bikes, e-rickshaws, and e-cars. In the last few years, lithium-ion batteries have been able to effectively penetrate into the automotive market due to its long life and low maintenance costs as compared to traditional batteries, such as lead-acid and nickel-metal hybrid batteries. Growing demand for electric vehicles, compact size, less charging time and low maintenance cost are some of the factors that are driving the global automotive lithium-ion battery market. In addition, the regional government’s push towards the adoptability of electric vehicles (green vehicles), in order to, reduce the carbon footprint, is further, propelling the growth for the automotive lithium-ion market. However, factors such as high cost, due to the limited number of automotive lithium-ion battery manufacturing players and the limited number of charging stations are restricting the growth of the market. Specifically, in 2019, the automotive lithium nickel manganese cobalt batteries (NMC) are anticipated to capture the highest share of about 35.3% in the global automotive lithium-ion battery market; these batteries are likely to continue leading throughout the forecast period as well. NMC chemistries are known to increase the energy density and lifespan of lithium-ion batteries. Hence, players are investing in NMC batteries. For example, Tesla ‘s top-selling car models, Model S and Model X, are equipped with NMC batteries and the company is now focusing on developing an NMC battery that can run over 1lakh km in a single charge. In addition, it is estimated that globally, more than 28 million lithium-ion batteries equipped electric four-wheelers will be sold by 2030. Since, in Q3, 2019, Tesla and Chevy bolt sold more than 50,000 electric cars in the US. The global automotive lithium-ion battery market has been segmented into four regions, namely, North America, Europe, Asia-Pacific and the Rest of the world. Specifically, lithium-ion batteries in the automotive sector are witnessing significant growth in countries, such as China, the US, and certain European regions. At present, China is the biggest market for both in terms of manufacturing lithium-ion batteries for electric vehicles and their consumption. At present, partnerships are one of the key business strategies of the players. For instance, in September 2019, Maruti Suzuki partnered with Toshiba and Denso to set up the world’s largest automotive lithium-ion battery manufacturing unit in Gujrat (India). Some of the leading players of the automotive lithium-ion battery market are Denso Corporation, Toshiba Corporation, Exicom Power Solutions, Johnson Controls Inc., A123 Systems Inc. LG Chem Ltd., Contemporary Amperex Technology Ltd. (CATL), BYD Company Ltd., Panasonic Corporation, and Samsung SDI Co. Ltd. among others.  The automotive lithium-ion battery market is segmented based on battery type, vehicle type, capacity type, and region. Based on battery type, the market is classified into Lithium Titanium Oxide (LTO), Lithium Nickel Manganese Cobalt Oxide, and Lithium Iron Phosphate. Based on vehicle type, the market is categorized into Two-wheeler EVs, Three-wheeler EVs, and Four-wheelers EVs. On the basis of capacity type, the market is bifurcated into 5-25Wh,48-95Wh,100-250Kwh and more than 250 kWh. Based on geography, the market is categorized in North America, Europe, Asia-Pacific and the Rest of the World. Scope of the Report The ‘Automotive Lithium-Ion Battery' report features an extensive study of the current landscape of industry players that are offering various types of lithium-ion batteries to the automotive industry. Amongst other elements, the report features: Detailed quantitative analysis of the market in terms of market size and forecast 2019-2030 An in-depth qualitative analysis of the automotive lithium-ion market in terms of key market trends, market drivers, restraints, and opportunities Key insights into the competitive landscape of the market.

...read more
Novel Clinical Trial Service Providers: Focus on Real World Data Based Trial Services, Virtual Trials, Adaptive, Umbrella and Basket Design, 2019-2050

The process of developing novel and effective healthcare products is both cost and time intensive. Studies suggest that each prescription drug requires around 10 years and over USD 2.5 billion in working capital before it reaches the market. Further, it is estimated that, in the US, 40% of the pharma industry’s R&D budget is spent solely on conducting clinical trials.  In addition to excessive capital requirement, clinical research is fraught with various other challenges, such as inefficient data handling, risk of failure / termination and a myriad of difficulties associated with patient recruitment and retention. Estimates suggest that nearly 85% of clinical trials fail to retain enough patients for successful study conduct. Patient recruitment and retention-related concerns have been associated with massive delays, with over 90% of clinical trials failing to comply to predetermined completion dates, due to poor participant accrual and excessive subject dropout. Such delays are estimated to result in capital losses of USD 8 million, per day, for a blockbuster drug.   Another prominent area of concern is related to the handling of clinical data, which results in delays in data analysis and preparation of outcome reports. Over the years, the pharmaceutical industry has leveraged technological advances to address several of the aforementioned clinical trial-related constraints / challenges. In fact, the clinical research segment has recently witnessed a surge in the availability of vendors, offering a diverse range of services and solutions for conducting and managing various aspects of trials. Apart from novel clinical trial designs, other advances in this domain include the application of decentralized clinical trial models, use of real-world evidence for clinical research, adoption of advanced clinical supply management solutions and introduction of various patient engagement tools. Many of the aforementioned concepts / solutions have demonstrated the potential to disrupt the conventional method of conducting trials, enabling the establishment of a more patient centric approach to drug development research. Such novel initiatives have also received significant funding from both private and public investors. We are led to believe that the ongoing efforts to improve drug / therapy development research are likely to boost the overall growth of the pharmaceutical market in the coming years. The ‘Novel Clinical Trial Service Providers: Focus on Real World Data Based Trial Services, Virtual Trials, Adaptive, Umbrella and Basket Design, 2019-2050’ report features an extensive study of the current landscape of industry players that are offering various types of innovative clinical research platforms / solutions to the pharmaceutical and life sciences industries. Amongst other elements, the report features: An overview of the current market landscape of companies offering solutions for virtual clinical trials, adaptive trial designs, clinical operations management and real-world evidence based clinical trials, featuring information on year of establishment, geographical location, company size and type of offerings. It also includes a list of virtual clinical trials, clinical studies that have used / are using innovative designs (adaptive trials, basket trials and umbrella trials), and a case study on clinical trials being conducted in real-world settings; the studies are analyzed on the basis of various parameters, such as location of the trial site, target indication, trial phase and study start-date. Brief profiles of companies offering solutions for virtual clinical trials, adaptive trial designs, clinical operations management and real-world evidence based clinical trials, featuring information on their year of establishment, respective headquarters, company size, key executives, service / technology portfolio, recent developments and an informed future outlook. A study of prevalent and emerging trends in the domain, as observed on the social media platform, Twitter. The analysis takes into consideration tweets posted on the platform, between 2013 and 2019 (till March), related to virtual trials, innovative trial designs and patient centricity.  A case study on the initiatives of big pharma players related to virtual clinical trials, offering insights on such clinical studies that have been conducted / planned by the aforementioned players, along with details on associated constraints and the future plans of players engaged in this domain. An analysis of the investments made at various stages of development in companies that are focused in this area, including seed financing, venture capital financing, debt financing, grants, capital raised from IPOs and subsequent offerings. One of the key objectives of the report was to understand the primary growth drivers and estimate the future opportunity of the market for virtual clinical trial services, adaptive trial design services, real-world evidence based clinical trial services and clinical operations management services. Based on parameters, such as number of pre- or post-approval studies conducted annually, capital investments made in these studies, and the likely cost and time saving opportunities, we have provided an informed estimate of the likely evolution of the market for virtual clinical trials, adaptive trial designs, clinical operations management and real-world evidence based clinical trials, in the short to mid-term and mid to long term, for the period 2019-2050. The report also features the likely distribution of the current and forecasted opportunity across [A] different therapeutic areas (cardiovascular disorders, infectious disorders, metabolic disorders, neurological disorders, oncological disorders and others), [B] end-users (small-sized players, mid-sized players, large players and academia / others) [C] phase of development (phase I, phase II, phase III and phase IV) and [D] key geographical regions (US, Europe, Asia-Pacific and Rest of the World). In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth. The opinions and insights presented in this study were influenced by discussions conducted with multiple stakeholders in this domain. In addition, the report features detailed transcripts of interviews held with the following individuals (in alphabetical order of company names): Phillipe Lemmens (Chief Operating Officer, Andaman7) Himanshu Verma (Founder and Chief Executive Officer, ConsilX) and Rajesh Jain (Co-Founder, ConsilX) Greg Erman (President and Chief Executive Officer, EmpiraMed) Jonathan Moshinsky, Head of Market Strategy, uMotif All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

...read more
Blockchain in Genomic Data Management: Market Landscape and Competitive Insights, 2018-2030

The success of the Human Genome Project resulted in the generation of large volumes of genomic data, which is extensively used in biotechnology and medical research. Further, advancements in high throughput gene sequencing technologies have enabled scientists to expedite the genome sequencing process, and achieve significant cost benefits as well. In fact, it is estimated that, by 2025, around 15% of the world’s population will have had their genomes sequenced, resulting in the generation of several zettabytes of data. However, currently, there are not many reliable and secure data management resources that offer secure storage, seamless exchange of information, and a reliable transaction platform, for large volumes of genomic and clinical data. Therefore, at this stage, it has become important to develop and establish the necessary tools and technologies to effectively help with the processing and analysis of the aforementioned information and for making it easily accessible to practicing physicians, scientists, pharmaceutical companies and other stakeholders. The blockchain technology has emerged as a viable option to store / exchange genomic data. The decentralized information management model used in blockchains has demonstrated significant benefits in banking and the fintech industry. Moreover, cryptocurrencies, which are based on the blockchain technology, are considered to be a powerful tool for peer-to-peer transactions without involving a third party to track the exchange. In the field of genomics, blockchain can act as a trusted means of carrying out transactions between data owners and data users (research groups / pharmaceutical companies). Moreover, such platforms enable easy access to genomic datasets, thereby, significantly improving the information procurement process for research studies related to personalized drugs / therapies. As a result, many companies have undertaken initiatives to promote the use of the blockchain technology for genomic data management. In fact, the growing importance of blockchain for managing genetic information and using it in healthcare decision-making is also evident in the number of tweets (~1,750) posted on the social media platform, Twitter, in the recent years. In the past few years, recent activities in this domain, such as the establishment of strategic partnerships (involving pharmaceutical players and relevant government bodies) and investments by venture capital / other stakeholders, indicate that the concept of using blockchain platforms for the storage and management of genetic information is gaining traction in the healthcare industry. We believe that such efforts are likely to boost the overall growth of this market in the coming years.   Scope of the Report The ‘Blockchain in Genomic Data Management: Market Landscape and Competitive Insights, 2018-2030’ report features an extensive study on the industry players that are offering blockchain platforms for the storage and management of genomic data. Amongst other elements, the report features: An overview of the current status of the market with respect to companies providing blockchain platforms, along with information on year of establishment, geographical location, company size, type of business model used, types of services offered to data owners and data users (pharmaceutical companies / research institutes), proprietary blockchain platforms and utility tokens, and end-users (pharmaceutical companies, research institutes, genomic data providers (patients and healthy individuals), software developers, and insurers). Tabulated profiles of all the players engaged in this field, featuring a brief overview of the company, and details on funding (if available), types of service(s) offered, proprietary blockchain platforms and utility tokens, key historical milestones, information on partnership(s) (if available), recent development(s) and roadmaps / future plans (if available). An analysis of the prevalent and emerging trends related to this domain as represented on the social media platform, Twitter, highlighting the most frequently talked about utility tokens, active players, and influential authors. It includes an insightful sentiment analysis, summarizing the impact / influence of various tweets posted on the platform. A comparative analysis of the needs of different stakeholders (pharmaceutical companies, research institutes, patients, healthy individuals, insurers and government agencies) in this industry. A detailed analysis highlighting the various business models and go-to-market strategies adopted by companies involved in this space. It features details on the various channels adopted / being adopted by companies to raise awareness and promote the use of their proprietary products / services. An informative bubble analysis, highlighting the market capitalization of the utility tokens of different companies engaged in this domain, based on total maximum supply, circulating supply and token price. A list of recent use cases of blockchain platforms, by pharmaceutical companies, highlighting the ways in which such tools / services have been used to manage and analyze genomic data. An insightful opportunity analysis, featuring an estimation of the existing market size; based on multiple parameters, we have also provided an informed estimate on the potential growth opportunities for companies engaged in this domain over the period 2018-2030. An analysis of various developments / recent trends related to companies offering blockchain platforms for genomic data management, offering insights on [A] instances wherein companies have raised funds to support their respective initiatives, [B] partnership and collaborations established within the industry, [C] other initiatives undertaken by different companies, [D] recent global events (summits, conferences and annual meetings), and [E] views expressed / opinions of selected key opinion leaders / industry experts on social media platforms, such as YouTube. The opinions and insights presented in this study were also influenced by discussions conducted with several stakeholders in this domain. The report features detailed transcripts of interviews held with the following individuals: David Koepsell (Chief Executive Officer, EncrypGen) Jake Dreier (Director of Growth and Operations, SimplyVital Health) Aldo de Pape (Chief Executive Officer, Genomes.io) and Louis Gooden (Analyst, Genomes.io) All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

...read more
Pharmaceutical and Life Sciences Real World Evidence: Market Landscape and Competitive Insights, 2018-2030

The process of developing new and disruptive medical products involves heavy investments, both in terms of time and cost. Estimates suggest that each prescription drug requires an average of about 10 years and over USD 2.5 billion in working capital before it gets commercialized. In order to gain regulatory approval and establish standards for the safety and efficacy of these products, randomized clinical trials (RCTs) are conducted; these account for a staggering 40% of the pharmaceutical industry’s budget.In addition to excessive R&D costs, these trials are fraught with various other challenges, such as prolonged delays and risk of failure / termination. It is also worth highlighting that most clinical trials are conducted under controlled conditions and involve a fairly homogenous patient population; however, when such products are approved, there are a variety of factors (both genetic and environmental) that need to be considered while treating individual patients. Data generated from real world applications of drug / therapy products partly addresses the aforementioned complexities and serves to complement the insights derived from controlled RCTs. Real world evidence has demonstrated the potential to validate the therapeutic value of pharmaceutical products and help customize product development in a more patient centric manner. In December 2016, the 21st Century Cures Act was passed directing the FDA to evaluate the applications of real world evidence in supporting healthcare decision-making. Its numerous applications have further encouraged pharmaceutical companies and health economists to utilize it in the evaluation of product candidates targeting even the rarest of medical conditions. In fact, it is estimated that, on an average, a big pharmaceutical company spends nearly USD 20 million annually for generating real world evidence-based insights. The growing importance of real world evidence in healthcare decision-making is also evident from the number of tweets (~4,400) posted on the social media platform, Twitter, in recent years. It is also worth noting that, since 2017, close to 75 global events (which include summits, forums, conferences and annual meetings) have been organized to discuss different aspects of real world evidence. Further, in the past few years, more than 1,000 studies have been initiated by stakeholders in real world setting to assess the impact of pharmacologic / non-pharmacologic treatment on patients and healthcare systems. Various initiatives are underway to further explore the potential of real world evidence in different stages of drug development. We believe that such efforts are likely to boost the overall growth of this market in the coming years.   Scope of the Report The ‘Pharmaceutical and Life Sciences Real World Evidence: Market Landscape and Competitive Insights, 2018-2030’ report features an extensive study on the industry players that are offering real world data / analytics / services to the pharmaceutical and life sciences industries. Amongst other elements, the report features: An overview of the current status of the market with respect to the companies providing real world evidence related solutions. It features information on their year of establishment, geographical location, size of the company, type of offering (real world data, analytics, and services), real world data sources (medical claims, clinical trials, clinical setting, pharmacy, patient-powered and others), and intended application areas (early stage research, clinical development, regulatory submission / reimbursement / market access, and post-approval studies). An elaborate discussion on data governance and the existing regulatory framework related to real world evidence across various geographies, namely North America (the US and Canada), Europe (the UK, Germany, France, Spain and Italy), and Asia-Pacific (Australia, China and Japan). A detailed publication analysis of close to 500 articles that have been published since 2016, highlighting the key focus areas of ongoing real world evidence-based research activity in the pharmaceutical and life sciences industries. The analysis also highlights the key prevalent trends associated with these publications, including information on the types of real world data sources utilized, leading indications, active stakeholders, and the most popular journals within this domain. A comprehensive analysis of completed, ongoing and planned studies conducted in the real world setting. For the purpose of this analysis, we considered only those studies that have been last updated since 2013, and analyzed them on the basis of various parameters, such as current trial status, regional distribution, type of sponsor, target indications, and enrolled patient population across different geographies. An analysis depicting the prevalent and emerging trends related to this domain as represented on the social media platform, Twitter. In addition to providing information on yearly trends related to the volume of tweets since 2013, the analysis highlights the most frequently talked about real world data sources, applications, therapeutic areas, active players, and influential authors. An in-depth analysis of recent events (summits / forums / conferences / annual meetings) that were organized for stakeholders in this domain, highlighting the evolution of discussion topics related to real world evidence. The analysis also provides details on event type, regional distribution, emerging agendas, popular organizers, active industry and non-industry players, and a schematic mapping of upcoming planned events. A discussion on affiliated trends, key drivers and challenges, under a SWOT framework, featuring a Harvey ball analysis, highlighting the relative impact of each SWOT parameter on the overall real world evidence market. A comparative analysis of the needs of different stakeholders (manufacturers, regulators, payers, providers and patients) involved in this domain. A list of recent use cases where real world evidence was leveraged by pharmaceutical / medical device companies, highlighting the ways in which companies have utilized such information to support regulatory decisions, advance disease understanding, and develop outcome-based reimbursement model. An insightful opportunity analysis, estimating the existing market size and potential growth opportunities across different applications (early stage research, clinical development, regulatory approval, pricing / reimbursement, and post-approval studies) of real world evidence. Based on multiple parameters, such as number of pre- or post-approval studies conducted annually, investment associated with these studies, and the likely cost and time saving opportunities, we have provided an informed estimate on the likely evolution of the market over the period 2018-2030. The opinions presented in this study were influenced by inputs (through a comprehensive survey) of several key players in this domain. In addition, the report features detailed transcripts of interviews held with the following individuals: Jane Reed (Head of Life Science Strategy, Linguamatics) Jonathan Moshinsky (Head of Market Strategy, uMotif) Anonymous (Vice President, Big Pharmaceutical Company) All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

...read more
Digital Health Market: Focus on Digital Therapeutic, Monitoring and Diagnostic Solutions, 2018-2030

Chronic disorders, such as diabetes, heart disease, obesity, mental health problems and insomnia, are considered to be the leading causes of death and disability across the world. These are largely considered to be the consequence of unhealthy lifestyle choices and exposure to harmful disease stimulants. According to a 2018 report published by the Center for Managing Chronic Disease at the University of Michigan, more than 50% of the global population currently lives with some form of chronic disease. Projections indicate that the global prevalence of diabetes (considered to be one of the fastest-growing chronic disease indications), is around 451 million, and is expected to reach 693 million by 2025. In addition, the World Health Organization (WHO) estimates that, at present, 450 million people worldwide are suffering from some form of mental health problem and / or neurological disorder. The increasing prevalence of such clinical conditions has imposed a significant burden on the modern healthcare system. In the US, the cost burden related to such long-term clinical conditions has been estimated to be approximately 86% of the USD 3.2 trillion that is spent by the country on healthcare, each year. Digital healthcare, a relatively new concept that emerged only a few years ago, is believed to possess the potential to address the rising concerns related to the growing socio-economic burden. Driven by the demand for self-management approaches, personalized healthcare solutions and customized treatment regimens made available in the home-care setting, digital health companies are presently engaged in developing several innovative solutions for therapeutic, surveillance and diagnostic use. Various digital therapeutics, through behavioral and psychological interventions, have been designed to have a direct impact on the chronic clinical conditions by providing motivational support and encouraging patients to make better lifestyle choices. Such therapeutics are available in a variety of gaming solutions, standalone software applications or combinations of the aforementioned solutions with personal coaching support, artificial intelligence (AI) support and medical device(s). A number of digital therapeutics have already been marketed and a significant proportion of such candidate therapies are in R&D phase. In order to introduce such unconventional products into the market, companies have followed multiple approaches, which include both B2B and B2C variants. It is also worth highlighting that certain companies are even attempting to offer reimbursements for their proprietary products by conducting clinical trials in order to establish therapeutic credibility and convince insurance providers and payers. Significant advancements have also been made towards the development of novel solutions for remote monitoring and diagnosis of chronic disorders. Such solutions have been developed to provide healthcare assistance in real-time through smartphone applications and connected devices. These solutions vary significantly in complexity and range from simple solutions capable of tracking weight loss, blood pressure, body temperature and heart rate to more sophisticated solutions that are equipped to independently conduct blood tests to confirm the presence of a bacterial / viral infection.   Scope of the Report The ‘Digital Health Market: Focus on Digital Therapeutic, Monitoring & Diagnostic Solutions, 2018-2030’ report features an extensive study of the current landscape and future outlook of the growing market for digital therapeutics, monitoring and diagnostic solutions that are either commercialized or under development within the healthcare industry. This burgeoning field presently offers a lot of opportunities to innovation focused start-ups and investors. Amongst other elements, the report features: A discussion on the current market landscape of digital therapeutics, monitoring and diagnostic solutions, featuring information on the various developers of digital solutions, along with information on their type of solution offered, primary disease area, mechanism of action, purpose of solution, status of development (discovery, research / development, approved and marketed), launch year (if applicable) and business channels being used by stakeholders in this domain. Detailed profiles of some of the emerging players in the industry, highlighting their current focus area(s), information on digital solutions offered and clinical research results (wherever available). Each profile also includes a section on recent developments and a comprehensive future outlook, highlighting the achievements, partnerships / collaborations, and the likely strategies that may be adopted by these players for future growth. A comprehensive product competitiveness analysis of digital therapeutics for the most popular therapeutic areas taking into consideration the product portfolio (based on the total number of digital therapeutics being developed in that disease area) and key specifications of the solution, such as disease management support, user motivation features, tracking of health data and others. A case study highlighting the focus area and results of clinical trials that have been conducted for the evaluation of various digital therapeutics. An analysis of funding and investments made into companies involved in this segment of the overall healthcare industry; the analysis covers information on seed financing, venture capital financing, debt financing, other equity financing and grants / awards received by these companies. An analysis of the partnerships that have been forged between companies in this domain in the recent past, covering clinical trial collaborations, product development and commercialization agreements, pilot product offerings, product integration and other relevant agreements. A detailed case study highlighting the various business models and go-to-market strategies adopted by companies involved in this space. It provides details on various channels being adopted by stakeholders in the industry to increase awareness and offer access to their proprietary products. A SWOT analysis capturing the key parameters and trends that are likely to influence the future of digital therapeutics market. One of the key objectives of the report was to understand the primary growth drivers and estimate the future size of the market. Based on multiple parameters, such as prices of digital solutions, indication / region specific adoption trends, distribution channels and competitive landscape, we have provided an informed estimate on the likely evolution of digital therapeutics and digital monitoring / diagnostic solutions till 2030. We have segmented the market by therapeutic areas (such as metabolic disorders, mental health disorders, cardiovascular disorders, substance use disorders, neurological disorders, chronic pain disorders, sleep disorders and respiratory disorders), distribution channels (B2C (patients) and B2B (healthcare providers, payers, employers and pharmaceutical companies)), purpose of solution (therapeutic or preventive), focus of solution (medication replacement or medication augmentation), type of solution (standalone software applications and software application + device or AI or personal coach) and key regions across the globe (North America (the US and Canada), Europe (Germany, France, Italy, the UK, Russia, and Spain), Asia-Pacific (China, Japan, India, Australia and South Korea) and rest of the world. In order to account for the uncertainties associated with the development of digital therapeutics and novel diagnostic / monitoring solutions and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market’s evolution. The opinions and insights presented in the report were also influenced by discussions held with senior stakeholders in the industry. The study includes detailed transcripts of discussions held with Adam Kaufman (Canary Health), Amelie Janson (Voluntis), Prayat Shah (Co-founder, Vice President, Partnerships, Wellthy Therapeutics) and Reshma Nayak (Vice President, Marketing and Communications, Wellthy Therapeutics), Stephanie Tilenius (Vida Health) and Vijay Ravindran (Floreo). All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

...read more
Next-Generation Batteries Market: Focus on Lithium Polymer, Printed, Solid-state, Thin Film and Ultra-thin Batteries, 2018-2030

Batteries are considered amongst the most remarkable man-made inventions in history and have been the focus of intense investigation by both scientists and engineers across the globe. Evolving from the primitive Voltaic Pile (the first electrical battery created in 1799), which used zinc and copper electrodes and brine-soaked paper as an electrolyte, a wide range of batteries are now available in the market. Amongst these, lithium-ion (Li-ion) batteries have long been considered a breakthrough in the battery landscape, resulting in revolutionary growth in the chargeable consumer electronics industry. It is estimated that, at present, more than one billion rechargeable Li-ion cells are produced each year to cater to the demands of the portable electronics market alone. However, despite thier successful market deployment, excellent energy density and cost-effectiveness, certain limitations, such as concerns related to the use of liquid electrolytes (risk of leakage and flammability), have also been associated with Li-ion batteries. A case-in-point being Samsung’s massive global recall of its Galaxy Note 7 series of mobile phones in September 2016, due to the safety issues associated with the Li-ion batteries used in them. It is also worth highlighting that a wide variety of niche and disparate application areas, such as miniature medical devices, smart wearables, wireless sensors / IoT devices, radio frequency identification (RFID) tags, powered smart cards, cosmetic patches, smart labels / packaging, electric / hybrid vehicles, and energy storage systems have surfaced in the past few years. Most of these advanced technology-enabled applications require new form factors and designs that conventional Li-ion batteries are unable to provide, pertaining to their size and safety limitations. These drawbacks have opened the door to immense innovation opportunities and added a new dimension to the competition amongst global battery developers, resulting in the establishment of next-generation battery technologies. In contrast to the conventional Li-ion batteries, next-generation product chemistries, which include lithium polymer, printed, solid-state, thin film and ultra-thin films batteries, have been proven to be safe under abusive conditions, demonstrated significant improvements in terms of overall performance, and are environmental-friendly. Moreover, owing to their flexible form factor, it is believed that these batteries can offer virtually limitless flexibility in term of design, materials and construction. At about 1/10th of the thickness of the thinnest prismatic liquid Li-ion cells, next-generation batteries have demonstrated significant potential to serve various upcoming markets. As a result, these batteries have captured the interest of several stakeholders in this industry; in fact, since 2010, over 7,000 patents have been published on next-generation battery technologies. It is anticipated that as the market becomes more mature, it is likely to benefit from economies of scale, resulting in further performance improvements and cost reductions.   Scope of the Report The ‘Next-Generation Batteries Market, 2018-2030’ report features an extensive study of the current landscape and future outlook of the growing opportunities for next-generation batteries (beyond Li-ion). The focus of this study is on advanced battery chemistries that are currently being developed / have already been developed, such as lithium polymer (LiPo) batteries, solid-state batteries, thin film batteries, printed batteries and other advanced variation of Li-ion batteries, and the likely evolution of these novel concepts in the mid to long term. Backed by funding from several venture capital firms and strategic investors, this evolving market has its hopes pinned on the efforts of a significant number of start-ups, small-and mid-sized companies. Amongst other elements, the report features: A detailed assessment of the current market landscape, providing information on various types of next-generation batteries, their respective specifications (such as thickness, capacity, voltage, operating temperature, cycle life / shelf life and chargeability), and targeted application areas. Elaborate profiles of some of the leading players in the industry, highlighting the current focus of various companies, financial information, proprietary battery technologies and specific products. Each profile also has a section on recent developments, highlighting the achievements, partnerships / collaborations, and the likely strategies that may be adopted by these players to fuel growth in the foreseen future. An in-depth patent analysis to provide an overview of how the industry is evolving from the R&D perspective. For this analysis, we looked at the patents that have been published by various industry players since 2010, across different types of next generation batteries. The analysis also highlights the key trends associated with these patents, including patent type, regional distribution, CPC classification, IP litigations, emerging areas and leading industry players. A comprehensive benchmark analysis, highlighting the key focus areas of small, mid- and large-sized companies; primarily, it provides a means to compare the existing capabilities of companies within and beyond their peer groups, and help them identify ways to achieve a competitive edge over contemporary players. An analysis of investments made at various stages of product development; these include seed financing, venture capital financing, debt financing and grants / awards received by the companies that are operating in this area. One of the key objectives of the report was to understand the primary growth drivers and estimate the future size of the market. We have provided an informed estimate on the likely evolution of the market for the period of 2018-2030 across several potential application areas of next-generation batteries, such as consumer electronics, electric vehicles, medical devices, powered smart cards / smart labels, RFID tags, smart wearables and wireless sensors / IoT devices. In addition, on the basis of the likely usability of different next-generation battery types across aforementioned applications, we have provided the distribution of the market across various types of batteries, such as lithium polymer, printed, solid-state, thin film, ultra-thin and other types of advanced Li-ion batteries. The forecast also includes distribution of the market opportunity across major regions of the globe, namely North America, Europe and Asia-Pacific. Considering the uncertainties related to investments and large-scale production of next generation batteries across different geographies, and to add robustness to our model, we have provided three forecast scenarios, representing the conservative, base and optimistic tracks of the market’s evolution. The opinions and insights presented in this study were influenced by discussions conducted with several stakeholders in this domain. The report features detailed transcripts of interviews held with the following individuals: David A. Ainsworth (CEO, OXIS Energy) Graeme Purdy (CEO, Ilika) Jeff Sather (VP, Technology and Customer Solutions, Cymbet) Lisa Hsu (Spokesperson and Deputy Marketing Manager, ProLogium Technology) Pritesh Hiralal (CEO, Zinergy UK) Xiachang Zhang (Chairman, Enfucell) Yuan Yang (Assistant Professor, Columbia University, New York) All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

...read more
Smart Grids Infrastructure Market, 2018-2030

With growing electricity consumption, the peak electricity demand is expected to increase manifold by 2050. It is believed that, owing to their intelligence features, smart grids have the potential to reduce the projected peak demand increases by up to 24% across some of the major regions of the world. This is because sensors in smart grids can detect peak load in advance and divert surplus supply from low demand areas to meet the peak requirements in a particular region.Moreover, with countries having ambitious renewable energy targets, it is important to ensure that a compatible infrastructure is put in place in parallel. Several geographies across the world have already recognized the need of upgrading to smart grids and have taken initiatives to encourage this transition. The US, for instance, allocated USD 4.5 billion initially towards grid modernization; the investment increased over the years under the American Recovery Reinvestment Act of 2009. In Europe, the European Technology Platform (ETP) SmartGrids was formalized in 2005 to create a vision for the European networks till 2020 and beyond. A recent 2017 report by Joint Research Centre (JRC) included 950 smart grid projects (R&D and demonstration) across Europe; across these, a total of EUR 5 billion has been invested. Emerging economies are also planning to upgrade existing systems to smart grids. The ambitious renewable energy targets of countries such as China and India are expected to drive the smart grids market in the future. In China, the government announced an investment of USD 96 billion between 2010 and 2020 to accelerate smart grids deployment. Similarly, in India, several pilot stage smart grid projects are underway. Smart Grids are expected to play a pivotal role in clean energy initiatives. Specifically, smart meters are amongst the most focused infrastructures across several countries. In the US, more than 75 million smart meters had been installed by 2017.In addition, the EU has set a target of replacing at least 80% (~ 245 million) of the conventional electricity meters with smart meters by 2020. In fact, it is reported that Sweden, Finland, Italy and Luxembourg have already reached full deployment.The EU Smart Grids Task Force believes that the planned rollout of smart meters and smart grids has the potential to reduce carbon emissions in the EU by 9%.   Scope of The Report The ‘Smart Grids Infrastructure Market, 2018 - 2030’ report features an extensive study of the current landscape and future outlook of the growing market for smart grids. The focus of this study is on the smart grids infrastructure, equipment, modules / components / systems offered by different players. The field is backed by grants / investments from various government agencies and is characterized by the presence of several well-established companies. Amongst other elements, the report features: A detailed assessment of the current market landscape, providing information on various infrastructure components offered by companies for deploying smart grids in an existing network; these include transmission and distribution equipment, substation automation modules / components and supported communication channels. Detailed profiles of some of the leading players in the industry, highlighting the current focus of the companies with details on their specific smart grid infrastructure equipment / module / component / systems and services. The profiles also include a section on recent developments, highlighting the achievements, partnerships / collaborations and the likely strategies that may be adopted by these players to fuel growth in the foreseen future. A comprehensive benchmark analysis, highlighting key focus areas of small, mid-sized and large sized companies; the benchmark analysis provides a means to compare the existing capabilities within respective peer groups and help industry stakeholders identify ways to achieve a competitive edge over contemporary players. A detailed market attractiveness analysis elucidating the attractiveness of major markets across the globe based on parameters that are likely to determine the future growth opportunities in specific regions. A case study highlighting the regulatory initiatives across various geographies and the regulatory standards / norms designed for a uniform and standardized smart grid deployments. An overview of some of the recent smart grid deployment projects across the EU, North America and rest of the world (Australia, China, India, Japan and South Korea). Specifically, we have highlighted the current focus area across the regions defined by the type of projects that have been undertaken (AMI, distribution network or transmission network). One of the key objectives of the study was to understand the primary growth drivers and estimate the future size of the market. We looked at the likely future investments to be made in the key geographies (the US, the EU, China, Japan, South Korea, Australia, Canada, Russia, Singapore, India and UAE). Based on this, we have provided an informed estimate on the likely evolution of the market in the long term, for the period of 2018 - 2030. Considering the uncertainties related to the investments and political influence across the geographies, and to add robustness to our model, we have provided three forecast scenarios, representing the conservative, base and optimistic tracks of the market’s evolution. The opinions and insights highlighted in this report were influenced by discussions held with senior stakeholders in the industry. These include Emmanuel Albert (CEO, Trispectra Innovation), Fulvio Ferrari (Founding Partner, Wemworld) and Jenny Erwin (Business Development Manager, Smart Wires). All the actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless specified otherwise.

...read more
Cybersecurity in Healthcare, 2018-2030

The digital revolution has transformed the way businesses operate across the globe. However, digitally stored information is prone to hacking and manipulation by cyber criminals. The concern is validated by the fact that more than 5.1 million records are compromised due to data breaches every day. In 2016, close to 1,800 incidents of data breaches were reported across all the industries; in total, almost 1.4 billion data records were lost or stolen. The year 2017 also witnessed several cyberattacks; notable examples include WannaCry and NotPetya ransomware attacks, Equifax data breach, MongoDB databases leak, Elasticsearch server hack, Cloudbleed security bug, Zomato hack, HBO hack / Game of Thrones leaks, Uber data breach, and Ethereum hack. The healthcare industry has been amongst the prime targets for hackers over the last several years. The Ponemon Institute’s Fifth Annual Study reported that cyberattacks in healthcare have increased by a factor of 125% since 2010. In the first half of 2017, the healthcare industry had been compromised a number of times, having experienced a total of 228 data breaches, representing 25% of the total number of breaches worldwide. Across these instances, around 31 million records were compromised, stolen or lost, representing an increase of 423% as compared to the first six months of 2016. In addition, according to a report published in May 2016, it is estimated that, with each electronic health record (EHR) costing around USD 355 in the black market, healthcare data breaches have resulted in losses worth USD 6.2 billion per year to the US healthcare industry. Examples of organizations that have recently been the victims of cyberattacks / security incidents include (in alphabetical order) Abbott / St. Jude Medical, Anthem BlueCross BlueShield, Bayer, Bupa Global Health Insurance, Bronx Lebanon Hospital Center, HealthNow Networks, Johnson & Johnson, Med Center Health, Merck, National Health System (NHS), Pacific Alliance Medical Center, Patient Home Monitoring, and Smiths Medical. In order to overcome these challenges, various cybersecurity solution providers have started to specifically focus on healthcare. Along with the presence of big companies, the entry of several start-ups is driving the innovation in this domain. Contrary to the expectation, capital spending on cybersecurity in the healthcare industry is far less compared to some other industries. In addition, the scarcity of skilled cybersecurity professionals capable of catering to the complex regulatory demands in the healthcare industry is making it even more difficult for the successful implementation of cybersecurity policies across this field.   Scope of the Report The ‘Cybersecurity in Healthcare Market, 2018-2030’ report features an extensive study of the current landscape and future outlook of the growing market of cybersecurity within the healthcare industry. The focus of this study is on the cybersecurity products / solutions and services that are currently available for protecting internet connected devices against cybercriminals, and the likely evolution of novel technologies / platforms in the mid to long term. Backed by funding from several venture capital firms and strategic investors, this evolving market has its hopes pinned on the efforts of multiple start-ups. Amongst other elements, the report features: A detailed assessment of the current market landscape of cybersecurity within the healthcare domain, providing information on cybersecurity core products / solutions, threat intelligence solutions, information on different threat types, security elements and modes of deployment. Detailed profiles of some of the emerging players in the industry, highlighting the current focus of the companies, capital raised, and details on their specific cybersecurity products / solutions and services. The profiles also have a section on recent developments, highlighting the achievements, partnerships / collaborations, and the likely strategies that may be adopted by these players to fuel growth in the foreseen future. A comprehensive benchmark analysis, highlighting key focus areas of mid to large sized companies, thereby, providing a means to compare the existing capabilities within respective peer groups and help industry stakeholders identify ways to achieve a competitive edge over contemporary players. In addition, we have provided detailed profiles of some of the established players within each peer group. An analysis of investments made at various stages of product development; these include seed financing, venture capital financing, debt financing and grants / awards received by the companies that are focused in this area. An elaborate valuation analysis of companies that are involved in providing cybersecurity products / solutions / services to the healthcare industry; for the purpose of this analysis, we focused on companies that have been established over the last 5-6 years. An overview of how artificial intelligence (AI), machine learning and deep learning techniques can augment cybersecurity, once integrated. In addition, we have outlined a detailed assessment of the current market landscape of AI-based cybersecurity, and provided high-level insights on the market competitiveness within this domain. A case study on cybersecurity use cases within the healthcare industry, highlighting some of the notable healthcare data breaches and security incidents that have happened in 2017. In addition, we have briefly outlined some of the recently reported medical device hacks / security vulnerabilities that led to the recalling of these devices. One of the key objectives of the report was to understand the primary growth drivers and estimate the future size of the market. Based on various parameters, such as number of healthcare data breaches, number of records compromised, expected pricing of the stolen medical records and spending trends on cybersecurity in the healthcare industry, we have provided an informed estimate on the likely evolution of the market in the long term, for the period 2018-2030. To account for the uncertainties associated with the number of data breaches, and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market’s evolution. The opinions and insights presented in the report were also influenced by discussions held with senior stakeholders in the industry. These include Garrett Silver (CEO, Critical Informatics), John Gomez (CEO, Sensato), Matan Kubovsky (VP, R&D, illusive networks), Mike Kijewski (CEO, MedCrypt), Mike Meikle (CEO, secureHIM), Robert Dobson (Director, Device Authority) and Rosa Lenders (Marketing Executive, Device Authority), Rod Schultz (CPO, Rubicon Labs) and Julia Cline (Senior Director, Product and Marketing, Rubicon Labs), Saïd Kenj (Account Executive, Cyberlytic) and Rebecca Bourke (Marketing Manager, Cyberlytic), Steve Leatherman (IT Consultant, BlackRidge Technology), and Yoni Shohet (CEO, SCADAfence). All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

...read more
Thin Film Photovoltaics Market, 2017 - 2030

The renewable energy industry has witnessed an unprecedented growth in the last few years, owing to the increasing energy demand and concerted efforts to prevent environmental damage. Factors, such as increasing population, advances in technology, rapid industrialization in emerging markets (such as China and India), rising standard of living, and globalization are driving the global demand. In fact, the global economy is predicted to grow three folds between now and 2050; this is anticipated to create a significant increase in demand for energy around the world. It is well known that, owing to the detrimental effects of non-renewable sources on the environment, the focus has shifted towards renewable energy sources. Amongst the available energy sources, non-renewables (including fossil fuels and nuclear energy) have a share of about 76.3% and renewables have a share of about 23.7%, in global electricity production. The Paris Agreement at the 21st Conference of Parties (COP), the first ever legally binding global climate deal, was signed by 195 countries in 2015, where it was decided to limit the global average temperature rise to 1.5C till the year 2100, by reducing carbon emissions. Even though quite recently, the US has decided to pull out of the agreement, other countries, such as China and India, are still optimistic about the success of the agreement. As a result of the aforementioned developments, there has been a rapid surge in installation of solar photovoltaics. In 2017 alone, about 74 GW of solar photovoltaics (PV) were installed across the globe, taking the cumulative installed solar PV capacity to over 300 GW. More growth is predicted in the future; the International Renewable Energy Agency (IRENA) has estimated that the global photovoltaic installations will reach between 1,760 GW and 2,500 GW by 2030. Historically, crystalline silicon (c-Si) photovoltaic cells have dominated the solar PV market, occupying a share of about 90%. However, it is believed that the cost reduction potential, as well as efficiency increase potential in case of silicon based photovoltaic modules are limited. Therefore, the industry’s focus is gradually shifting towards the use of thin film photovoltaic technologies. The growth of these technologies is also being driven by newer applications of solar panels, such as for building integrated photovoltaics (BIPV), rooftops / facades and applications that demand more flexibility, as well as low angle installations. As the demand for solar PV continues to rise at a steady pace, we are optimistic about the future of the thin film PV industry.   Scope of the Report The Thin Film Photovoltaics Market, 2017-2030 report provides a comprehensive analysis of the current market landscape and a detailed future outlook of the thin film photovoltaics (PV) industry. As the global economy aims for energy security, renewable energy sources, such as solar power, are expected to play a pivotal role. In 2015, the solar energy sector attracted 56% of the total new investments (USD 286 billion) that were made in the renewable power and fuels industry. As a result of heavy funding and significant government support (in the form of subsidies), the prices of solar energy have plummeted by over 60% in the last 10 years. Our study encompasses the various thin film photovoltaic technologies that are currently available in the market, such as cadmium telluride (CdTe), copper indium selenide / gallium selenide (CIS / CIGS) and amorphous silicon (a-Si). We expect that, as this generation of thin film photovoltaic technologies matures, they are likely to benefit from economies of scale, resulting in further cost reductions. Subsequently, these technologies are likely to become one of the primary drivers behind the growth of the solar PV industry. In addition to aforementioned technologies, next generation thin film photovoltaic technologies, such as dye sensitized solar cells (DSCs), organic PV, and perovskite PV, are already being developed. These next generation thin film photovoltaic technologies are anticipated to gain more importance in the long term as they are believed to be superior in terms of energy generation capacity as well as flexibility. The study provides a deep dive into the developments that are impacting the current solar energy generation industry and are likely to drive significant changes in the long term. We were able to identify over 80 industry stakeholders, distributed across the three major thin film photovoltaic technologies. In addition to other elements, the study elaborates on the following: The current status of the market with respect to key players / technologies along with information on a company’s business model (whether it is focused on products or services or technology licensing or a combination of these), scale of operation (small, medium or large), substrate used, deposition process involved, cell / module capacity, conversion efficiency achieved, and geographical location of the companies. Comprehensive profiles of some of the key players across each type of thin film photovoltaic technologies, covering the current focus of the companies, details on their specific thin film PV technology, products and services, and associated recent developments & future outlooks. The impact of venture capital funding in this area. We believe that investments from private investors is a key enabler that is likely to drive significant developments in this industry in the long term. Investments from external sources generally enable stakeholders in the industry to scale-up their operations and develop / acquire the necessary technologies to carry out production at larger scales. This usually results in significant reductions in cost per unit. Next generation thin film PV technologies, such as dye-sensitized solar cells (DSCs), organic PV, and perovskite PV, with details on the key technologies involved, industry players focused in the area, current trends in the market, as well as future prospects. A high level patent analysis to provide an overview of how the industry is evolving from the R&D perspective. For this analysis, we looked at the patents that have been granted to various players in the last five years, across the current and next generation thin film PV technologies. Potential future growth in the thin film PV industry (both in terms of installed capacity and expected revenue generation) across the currently available technologies (CdTe, CIGS and a-Si). We have taken into account the overall installation cost of thin film PV modules to estimate future revenues. The report provides a comprehensive market forecast (till 2030) for the global, as well as the current top 10 regional solar PV markets, which includes the US, EU5 and Asia Pacific (Australia, China, India, and Japan), in terms of installed capacity. It also includes a segmentation by applications, distributed by small scale (such as consumer electronics), medium scale (such as residential rooftops and building facades) and large scale (such as solar parks, farms, plants), in terms of installed capacity and the potential revenues. The opinions and insights presented in this study were influenced by discussions conducted with several key players in this domain. The report features detailed transcripts of interviews held with Andreas Zimmerman (Owner, Sunplugged), Dieter Manz (Founder and CEO, Manz), Rombout Swanborn (Chairman, HyET Solar), Edward Hamers (CTO, HyET Solar) and Robin Quax (Production Engineer, HyET Solar).

...read more
Grid Scale Energy Storage Technologies Market, 2017 - 2030

It is predicted that the global economy will increase by three-folds between now and 2050. This, in turn, is likely to result in increased energy demands.According to Enerdata Energy Statistical Yearbook 2016, electricity demand has more than doubled between 1990 and 2015 to reach 20,568 TWh. This demand is projected to grow even further; in fact, by 2035, the growth is expected to be in the range of 69% to 81%. As the global economy aims for energy security, renewable energy sources such as solar and wind are expected to hold a key position in the future. However, a major constraint with such renewable sources is that energy is generated with a highly variable output in an intermittent manner. Therefore, the surplus energy is required to be stored so that it can be supplied during non-optimal generation periods such as at night time or when the wind is not blowing. Storage at a large scale has remained a major challenge; however, several developments have taken place in this domain and efforts are being made towards their feasible commercial deployments. A variety of grid scale energy storage technologies are known to the industry and can be broadly categorized based on the type of energy being stored. Pumped hydro energy storage (PHES) is a well-established energy storage technique; however, because of known challenges, various other energy storage techniques, backed by public and private lending, have surfaced over the last decade. For a market such as energy storage, which is linked to the economy of a country, initiatives related to policy decisions and mass awareness play a key role in the growth. Some countries have introduced reforms / amendments in the policies to encourage the market for energy storage, while others are still debating on it. The White House Summit 2016 is a recent example of such initiatives. At the summit, a range of utility, industry and government storage commitments were highlighted to signify the importance of this subject. Post this, the Federal Energy Regulatory Commission (FERC) started working on re-evaluating some of the policies to encourage energy storage in the US. At the time of release of this study, policies favoring renewable energy over other sources were in place in about 50 countries. The common theme across these policies is priority dispatch of electricity from renewable sources, special feed-in tariffs, quota obligations for renewable energy and energy tax exemptions. In addition, legal bindings / agreements, such as COP21, to tackle climate change are encouraging the use of renewable energy, which, in turn, is likely to drive the energy storage industry.   Scope of the Report The Grid Scale Energy Storage Technologies Market, 2017-2030 report provides a comprehensive analysis of the current market landscape and a detailed future outlook of the large scale energy storage technologies. The study highlights various energy storage technologies that are currently commercially available or are under development. These technologies can be classified as mechanical energy storage, chemical energy storage, electrochemical energy storage, thermal energy storage or electromagnetic energy storage technologies. The industry has long revolved around pumped hydro energy storage, which currently contributes close to 95% of the global energy storage capacity. However, several geographical and environmental constraints associated with it are likely to limit its growth in the long term. As a result, stakeholders have developed / are developing novel energy storage technologies to overcome the limitations of conventional systems. The primary focus of this study is on these novel / upcoming energy storage technologies, including different types of battery storage, compressed air energy storage, concentrated solar power / molten salt energy storage, flywheel energy storage and power-to-gas energy storage. The study provides a holistic coverage of the developments that are impacting the current energy storage setup and are likely to drive significant changes in energy management approaches in the long term. We were able to identify close to 170 energy storage technologies (excluding PHES) segmented across aforementioned categories. In addition to other elements, the study elaborates on the following: The current status of the market with respect to key players / technologies along with information on rated power, energy, duration / discharge time of the technologies and geographical location of the companies. Comprehensive profiles of some of the upcoming players under each energy storage category, covering details on the current focus of the companies, their specific energy storage technologies and associated recent developments / initiatives. Various investments and grants received by companies focused in this area to support their R&D activities, a key enabler that will continue to drive developments in the long term. In addition, respective governments have taken encouraging policy decisions, which have provided positive outlook to the energy storage industry. A case study on pumped hydro energy storage, where we have provided information on the plants that are currently operational as well as the ones expected to be operational in the near future. In addition, we have highlighted the historical trends that are likely to govern the future evolution. Key drivers and restraints for the growth of the grid scale energy storage market. Factors such as rising adoption of renewable energy sources, limitations of conventional energy storage systems and high electricity charges are likely to fuel the demand of energy storage systems. Potential future growth of the grid scale energy storage market (both in terms of installed capacity and expected revenue generation) across different technologies (CSP / molten salt energy storage, compressed air energy storage, lithium-ion batteries, lead acid batteries, flow batteries, flywheel energy storage, power-to-gas energy storage and other upcoming technologies). We have taken into account the levelized cost of energy storage to determine revenues for different energy storage technologies. The report covers forecast (till 2030) for the global as well as specific regional markets (North America, Europe, Asia and Rest of World) in terms of installed capacity. It also includes individual forecasts  on the installed capacity in specific countries, including the US, France, Germany, Italy, Spain, the UK, Ireland, China, India, Japan, South Africa, South Korea, Chile and Morocco, that are poised to witness healthy growth in the short-midterm and long term. Our opinions and insights presented in this study were influenced by discussions conducted with several key players in this domain. The report features detailed transcripts of interviews held with Anoop Mathur (CTO and Founder, Terrafore Technologies), Camilo Lopez Tobar (Business Development Manager, Electrochaea), Dr. Markus Ostermeier (Product Development Manager, Electrochaea), Eric Murray (President and CEO, Temporal Power), Itai Karelic (Vice President Business Development, EnStorage), John McCleod (Vice President Engineering, ZincNyx Energy Solutions) and Suresh Singh (President and CEO, ZincNyx Energy Solutions), Nicolas Velasco (Commercial Director, Albufera Energy Storage), Rainer Grumann (Vice President Sales, Heliocentris), Sonya Davidson (President and CEO, H2 Energy Now), and Tom Stepien (CEO and Co-founder, Primus Power).

...read more
Deep Learning in Drug Discovery and Diagnostics, 2017 - 2035

Deep learning is a novel machine learning technique that can be used to generate relevant insights from large volumes of data. The term Deep Learning was coined in 2006 by Geoffrey Hinton to refer to algorithms that enable computers to analyze objects and text in videos and images. Fundamentally, deep learning algorithms are designed to analyze and use large volumes of data to improve the capabilities of machines. Companies, such as Google, Amazon, Facebook, LinkedIn, IBM and Netflix, are already using deep learning algorithms to analyze users activities and make customized suggestions and recommendations based on individual preferences. Today, in many ways, deep learning algorithms have enabled computers to see, read and write. In light of recent advances, the error rate associated with machines being able to analyze and interpret medical images has come down to 6%, which, some research groups claim, is even better than humans. The applications of the technology are being explored across a variety of areas. Specifically in healthcare, the American Recovery and Reinvestment Act of 2009 and the Precision Medicine Initiative of 2015 have widely endorsed the value of medical data in healthcare. Owing to several such initiatives, medical big data is expected to grow approximately 50-fold to reach 25,000 petabytes by 2020. Since 80% of this is unstructured, it is difficult to generate valuable / meaningful insights using conventional data mining techniques. In such cases, deep learning has emerged as a novel solution. Lead identification and optimization in drug discovery, support in patient recruitment for clinical trials, medical image analysis, biomarker identification, drug efficacy analysis, drug adherence evaluation, sequencing data analysis, virtual screening, molecule profiling, metabolomic data analysis, EMR analysis and medical device data evaluation are examples of applications where deep learning based solutions are being explored. The likely benefits associated with the use of deep learning based solutions in the above mentioned areas is estimated to be worth multi billion dollars. There are well-known references where deep learning models have accelerated the drug discovery process and provided solutions to precision medicine. With potential applications in drug repurposing and preclinical research, deep learning in drug discovery is likely to have great opportunity. In diagnostics, an increase in the speed of diagnosis is likely to have a profound impact in regions with large patient to physician ratios. The implementation of such solutions is anticipated to increase the efficiency of physicians providing a certain amount of relief to the overly-burdened global healthcare system.   Scope of the Report The “Deep Learning: Drug Discovery and Diagnostics Market, 2017-2035” report examines the current landscape and future outlook of the growing market of deep learning solutions within the healthcare domain. Primarily driven by the big data revolution, deep learning algorithms have emerged as a novel solution to generate relevant insights from medical data. This continuing shift towards digitalization of healthcare system has been backed by a number of initiatives taken by the government, and has also sparked the interest of several industry / non-industry players. The involvement of global technology companies and their increasing collaborations with research institutes and hospitals are indicative of the research intensity in this field. At the same time, the pharma giants have been highly active in adopting the digital models. Companies such as AstraZeneca, Pfizer and Novartis continue to evaluate the digital health initiatives across drug discovery, clinical trial management and medical diagnosis. Some notable examples of such digital health initiatives include GSK and Pfizer’s collaboration with Apple for the use of the latter’s research kit in clinical trials, Biogen’s partnership with Fitbit for using smart wearables in clinical trial management, and Teva Pharmaceuticals’ partnership with American Well to use Smart Inhalers for patients with asthma and COPD. Backed by funding from several Venture Capital firms and strategic investors, deep learning has emerged as one of the most widely explored initiatives within digital healthcare. The current generation of deep learning models are flexible and have the ability to evolve and become more efficient over time. Despite being a relatively novel field of research, these models have already demonstrated significant potential in the healthcare industry. One of the key objectives of this study was to identify the various deep learning solutions that are currently available / being developed to cater to unmet medical needs, and also evaluate the future prospects of deep learning within the healthcare industry. These solutions are anticipated to open up significant opportunities in the field of drug discovery and diagnostics as the healthcare industry gradually shifts towards digital solutions. In addition to other elements, the study covers the following: The current status of the market with respect to key players, specific applications and the therapeutic areas in which these solutions can be applied. The various initiatives that are being undertaken by technology giants, such as IBM, Google, Facebook, Microsoft, NVIDIA and Samsung. The presence of these stakeholders signifies the opportunity and the impact that these solutions are likely to have in the near future. Specifically, we have presented a comparative analysis of the deep learning solutions developed by IBM and Google. Detailed profiles of some of the established, as well as emerging players in the industry, highlighting key technology features, primary applications and other relevant information. The impact of venture capital funding in this area. It is important to mention that since the industry has witnessed the emergence of several start-ups, funding is a key enabler that is likely to drive both innovation and product development in the coming years. An elaborate valuation analysis of companies that are involved in applying deep learning in drug discovery and diagnostics. We built a multi-variable dependent valuation model to estimate the current valuation of a number of companies focused in this domain. Future growth opportunities and likely impact of deep learning in the drug discovery and diagnostics domains. The forecast model, backed by robust secondary research and credible inputs from primary research, was primarily based on the likely time-saving and its associated cost-saving opportunity to the healthcare system. For the purpose of the study, we invited over 100 stakeholders to participate in a survey to solicit their opinions on upcoming opportunities and challenges that must be considered for a more inclusive growth. Our opinions and insights presented in this study were influenced by discussions conducted with several key players in this domain. The report features detailed transcripts of interviews held with Mausumi Acharya (CEO, Advenio Technosys), Carla Leibowitz (Head of Strategy and Marketing, Arterys) and Deekshith Marla (CTO, Arya.ai).

...read more
Smart Wearables in Healthcare, 2016-2030

Owing to the indispensable need of every individual to remain healthy, the healthcare sector has been a key element in the overall growth of society and economy. With the ever increasing global population that currently stands at 7.4 billion, healthcare management is a primary challenge as more and more people become aware about fitness and health. In order to address this challenge, the industry is obligated to revise, restructure and improve its services and methodologies. The trend has recently shifted towards the adoption of a more proactive approach in healthcare; this is being achieved by focusing on early detection of any / all adverse health conditions and implementing preventive measures. A blend of information technology within healthcare sector has resulted in several revolutionary developments for personalized healthcare. Examples of such innovations include genome sequencing, use of robots in healthcare and remote patient monitoring; in fact, smart wearables form a key component of remote patient monitoring while offering several associated benefits. Defined as wearables that contain active electronics such as sensors, audio / video feedback mechanisms and data processing / transmission capabilities, smart wearables are becoming quite popular amongst the masses. Such wearables allow an individual to monitor and share critical insights on his / her health with the physician without having to visit a healthcare professional. These wearables are generally classified as smart wrist wearables, smart patches, smart clothes, smart head / neck wear and smart ear / eye wearables while their applications span across activity / fitness tracking, monitoring & diagnostics, therapy and other areas. At present, smart wrist wearables dominate the market with presence of a large variety of wearables, primarily for activity / fitness tracking. Several start-ups, with innovative wearables, have surfaced in the past 6-7 years and have continuously encouraged the use of novel technologies. A sizeable proportion of these companies are focused on gaining foothold in the field of monitoring & diagnosis and wearables offering therapeutic benefits. The current market is primarily concentrated in North America and Europe; these regions have presence of a large number of companies focused on development of smart wearables. It is fair to state that, in the long term, emerging markets of Asia (specifically India and China) are likely to emerge as credible contributors; commoditized prices will be a significant factor that could result in mass adoption amongst the wide consumer base in these regions. The overall interest continues to rise as is evident from the number of partnerships / agreements that have taken place amongst the stakeholders. Product development agreements have been very common and are likely to play an active role in industry’s development. Moreover, several venture capital firms including (indicative list, in no specific order) Qualcomm Ventures, Intel Capital, Khosla Ventures, Mohr Davidow Ventures, Sanderling Ventures, DCM Ventures, ff Venture Capital and True Ventures have led multiple funding rounds in these companies, acting as a key enabler in the current ecosystem. A well distributed market of these next generation wearables across several stakeholders presents a good opportunity for evolution of innovative technologies. A stronger and more collaborative ecosystem amongst the wide variety of stakeholders could result in a significantly higher growth compared to what the industry has experienced in the recent past.   Scope of the Report The ‘Smart Wearables in Healthcare, 2016-2030’ report provides a comprehensive analysis of the current market landscape and a detailed future outlook of smart wearables focused on improving the quality of lives of people from a healthcare / fitness perspective. The report highlights the various applications of smart wearables across a wide range of sectors such as gaming, entertainment, healthcare / fitness and lifestyle. A significant amount of innovation in smart wearables industry is centred in the healthcare sector. The study provides a holistic coverage of developments that are impacting the current healthcare setup and are likely to drive significant changes in healthcare management approaches in the future. In fact, a close look at historical trends on social media platforms clearly indicates the growing popularity of smart wearables / devices amongst the masses. One of the key objectives of this study was to identify the various smart wearables that are currently available / being developed and evaluate the future potential of the market within the healthcare industry. Combined, these wearables offer a huge opportunity for their respective developers as the industry gets ready for the launch of next generation of these products. In addition to other elements, the study elaborates on the following areas: The current status of the market with respect to key players in this segment, specific applications (such as activity / fitness tracking, monitoring & diagnostics and therapy) and therapeutic areas these products intend to address. 2x2 matrices depicting product competitiveness and supplier power across the growing landscape of smart wearables to assess the likely influence such products will have in the future. Impact of venture capital funding as well as numerous partnerships inked between the stakeholders; it is important to stress that these are the two key enablers that will continue to drive developments in the near term. Detailed profiles of some of the established as well as emerging players in the industry highlighting key product features, user / professional reviews and other relevant information. Case study on the various components that are commonly used in smart wearables along with a list of manufacturers / service providers for these components. Potential future growth of smart wearables (both in terms of volume and value) across the different segments (wrist wearables, smart patches, smart clothes, head / neck wearables and ear / eye wearables) and application areas (activity / fitness tracking, monitoring & diagnostics and therapy). The report provides sales forecast for the global and specific regional markets (North America, Europe, Developed Asia and Rest of the World) till 2030. We have taken into account the price variation that is likely to happen because of mass acceptance and increased competition. For the purposes of the study, we invited over 150 stakeholders to participate in the study to solicit their opinions on upcoming opportunities and challenges that must be considered for a more inclusive growth. Our opinions and insights presented in this study were influenced by discussions conducted with several key players in this domain. The report features detailed transcripts of interviews held with Andrew Ronchi (CEO, dorsaVi), Anthony Gonzales (Co-founder and Executive Director, Force Impact Technologies), Jeff Sweeney (Director Market Development, Nortek Security & Control), Marc Paquin (Director Partnerships and Business Development, Hexoskin), Soulaiman Itani (Founder and Chief Technology Officer, Atheer), Steve Axelrod (President and Chief Executive Officer, G-Tech Medical) and Tansy Brook (Marketing Director and Research Lead, Lumo Bodytech).

...read more
Infusion Pumps Market, 2015-2025

Infusion pumps are a class of drug delivery devices that have found wide adoption across different application areas. Their popularity can be attributed to their reliable, user friendly features and ergonomic design. The market has a wide array of different types of infusion pumps (volumetric, syringe, implantable, elastomeric, ambulatory and others); combined, they offer a large range of infusion volume, flow rate, occlusion alarm pressure range and many other technical parameters that can be adjusted according to the patient’s requirements and care areas.These pumps have strengthened their position in a variety of application areas including oncology, diabetes, pain management, enteral feeding and general infusion. Several established firms as well as emerging players are currently competing in this market. Companies have regularly come up with technological advancements aimed at increasing the reliability and safety of these pumps. Examples of technological / design innovations include introduction of intuitive coloured touch screen, drug libraries, user friendly interface, compact design, improved accuracy, automated power saving mode and air-in-line detection.The introduction of “smart infusion pumps” has been an important step in the growth of this market. Despite the fact that the current market is significantly mature, a number of technological advancements from established and new players have sustained the growth momentum.Companies are continuously on the lookout for new avenues of growth in terms of novel features; this is expected to result in an even wider adoption going forward.   Scope of the Report The “Infusion Pumps Market, 2015-2025” report provides a comprehensive study of the current state of infusion pumps market and the likely future evolution of these devices over the next decade. The study covers various types of infusion pumps that are used across several application areas. The current generation of these devices, being reliable and easy to use, have found wide acceptance in both homecare and hospital market. In addition to providing a comprehensive market landscape, the report covers various other aspects such as market trends, recent partnerships and our opinion on the drivers that will likely influence the market in the short-term and long-term. We have also done an elaborate product competitiveness analysis across Oncology, Pain Management and Insulin Infusion pumps. This is supported by detailed profiles of leading devices, key features and how these features make a device different from others. Innovations in design and safety mechanisms will continue to present encouraging prospects to device manufacturers in the years ahead. This study also highlights some of the challenges associated with the development and use of these devices in the market. Regular modifications in design and incorporation of safety features present operational challenges to the manufacturers. Cost is another factor that can restrain the market, especially in case of some of the novel devices. However, the increasing focus on smart infusion pumps and advancements in the software and safety features will help in resolving these issues. The report also includes two special case studies. The first one is on accessories that are used with these pumps while the second case study focuses on ambulatory pumps that hold a significant portion of the homecare market. In addition, we have analysed the existing market size and potential future growth of these drug delivery devices across different application areas and product categories. The forecast, over the next ten years, has been presented both in terms of volume (number of units) and value (USD billion). It takes into account the likely price variation that will occur as a result of continued adoption and increased competition. The research, analysis and insights presented in this report are backed by a deep understanding of key insights gathered from both secondary and primary research. Actual figures have been sourced and analysed from publicly available information. Unless otherwise specified, all figures are presented in USD.

...read more
Pharmaceutical Anti-Counterfeiting Technologies Market, 2015-2025

The problem of counterfeit products has been a common challenge to all the industries across the globe. However, when it comes to the pharmaceutical industry, the issue primarily revolves around the health of patients rather than revenue losses in the industry. Counterfeit drugs create substantial public health hazards and cause crucial safety concerns. Falsified or substandard drugs can lead to adverse reactions / side effects and consequently lead to the death of a patient. The major challenge associated with a counterfeit drug is that a non-expert, such as a patient, cannot differentiate between genuine and counterfeit drug without the help of a special instrument or device. The packaging, shape and size of counterfeit drugs are made identical to that of an authentic drug by the counterfeiters. However, counterfeit drugs contain very less or no active ingredient; instead, they contain other useless and harmful materials such as dust, chalk or very low quality active ingredients posing serious threats to the patients. These issues have led to the development of many technologies that can be used to detect whether a drug is legitimate or fake. Apart from these technologies, many other significant measures have been taken by the pharmaceutical companies and government authorities to tackle this growing problem. The market can be categorised into two segments, Authentication Technologies (the technologies providing overt and covert security features) and Track & Trace Technologies (the technologies facilitating visibility of products throughout the supply chain). Specifically in the Authentication segment, technologies providing covert security features are very popular and occupy a major share in of the overall authentication market. These technologies are very difficult to mimic and require special instruments / devices for verification of drugs by the manufacturers. Managing supply chain, especially in case of pharmaceutical industry, is a big challenge. Pharmaceuticals supply chains are highly complex and therefore make it an ideal target for counterfeiters. However, recently many developments have taken place to overcome this challenge. Several countries across the globe have passed legislations, making it mandatory to implement serialisation by the manufacturers. Serialisation is being thought as a one stop solution to prevent counterfeiting in the pharmaceutical industry by securing the supply chain. The field has attracted several companies which have developed many technologies with an aim to prevent counterfeiting in the pharma industry. The overall interest continues to rise as is evident from the number of counterfeit incidents and various laws and legislations being passed throughout the world. Small companies that have developed anti-counterfeiting technologies are likely to play a very active role in the near future.   Scope of the Report The ‘Pharmaceutical Anti-Counterfeiting Technologies, 2015-2025’ report provides a comprehensive study of the growing market of anti-counterfeiting technologies being used in the pharmaceutical industry. This study provides extensive details on technologies which offer overt and covert features to enable verification of drugs. In addition, it reviews the different track and trace technologies which enable tracking of a product through the supply chain. Counterfeiting of products is a big concern in several industries such as electronics, cosmetics, tobacco, wine & spirits and fast moving consumer goods. Specifically, within the pharmaceutical market, the magnitude of the problem is relatively high as it has a direct impact on the health of the wider community. It is worth highlighting that the pharmaceutical market is highly attractive for counterfeiters due to several benefits such as high price of patented drugs, lack of proper legislations and high demand of medicinescompared to their supply. The primary goal of anti-counterfeiting technologies is to prevent counterfeiting of products; this is done by making it difficult to copy patent protected drugs as well as preventing entry of substandard or fake drugs into the product supply chain. The report covers multiple aspects such as key features of various technologies, scenario based future outlook of the market, SWOT analysis and our opinion on the likely drivers which will influence the market’s evolution. We have provided a holistic view of the market landscape including detailed profiles of leading technologies highlighting the process by which they prevent counterfeiting. Further advancements in such technologies will make them more cost effective, encourage a wider adoption and result in a more mature market in the years to come. In addition to the key benefits and the likely market drivers, this study also highlights some of the challenges associated with the use and implementation of these technologies in the pharmaceutical industry. Certain technologies require modifications in existing production processes and present operational challenges to the manufacturers. Cost is another factor that can significantly restrain the market. The report also includes two case studies on serialisation. We have looked at the regulations that have been implemented already or are likely to be implemented to prevent counterfeiting. Most of these regulations favour item level serialisation as a task to be accomplished by the pharmaceutical manufacturers in the near future. However, some stakeholders are of the opinion that authentication technologies are much more effective as anti-counterfeiting measures rather than just providing a unique number to each product (the case of serialisation). The report covers various techniques and measures that have the potential to combat the challenges related to counterfeit medicines. The scenario based forecast approach identifies short-midterm and long term market evolution for the period 2015-2020 and 2020-2025, respectively. The research, analysis and insights presented in this report are backed by a deep understanding of key insights gathered from both secondary and primary research.

...read more
Large Volume Wearable Injectors (2nd Edition)

The injectable drug delivery market holds significant potential for the future. From the conventional syringes with vials and painful needles to the modern-day pre-filled syringes, pen-injectors, needle free injectors and auto-injectors, the market has come a long way. The rising prevalence of chronic diseases is one of the key factors driving the companies to develop systems that allow patients to self-administer drugs. Taking the concept of self-injectors to a new stratum, ‘Large volume Wearable Injectors’ have surfaced recently. Also known as bolus injectors and non-insulin patch pumps, these devices not only offer a range of benefits to the end users but also provide a number of additional benefits to other stakeholders in the industry. One of the main drivers for the perceived growth of these injectors is the large number of biologics currently under development. A majority of these molecules are highly viscous and are required to be delivered in volumes of greater than 1 ml. The absence of devices which can safely administer these drugs is currently a big unmet need in the market. However, the early signs are encouraging. Despite the uncertainties related to the device development and approval, many companies are investing time, money and resources to develop novel devices. Some customized drug-device combinations are currently being developed for specific drugs such as Herceptin, AMG-145 and Furosemide. In addition, pharma companies have many undisclosed programs which are likely to provide the necessary growth impetus in the near future. This development is being led jointly by established firms such as Becton Dickinson, West Pharmaceuticals and emerging players such as Unilife, SteadyMed Therapeutics, Ratio Drug Delivery, Sensile Medical, Enable Injections and scPharmaceuticals. It is widely anticipated that, once ready, such devices which will allow self-administration of high viscosity, large volume biologics and be readily adopted in the industry.   Scope of the Report The ‘Large Volume Wearable Injectors’ market report provides a comprehensive analysis of the current state of the market and the likely future evolution over the next ten years. Starting with the basic introduction to these injectors, the report lays emphasis on the current unmet needs of the market. As all the large volume wearable injectors are currently only available for investigational use, the investment being done in this area is geared towards tapping the significant future potential of this market. In fact, one of the primary objectives of this report is to estimate the size of this future promise offered by such injectors. A large number of biologics are currently under development and a majority of these molecules are highly viscous and require to be delivered in volumes of greater than 1 ml. It is widely anticipated that devices which will allow self-administration of these molecules will be readily adopted by all stakeholders in the industry. For the purposes of our analysis, we followed a top-down approach to estimate the size of this market. This included: Conducting an extensive research to identify high viscosity and large volume biologics which are either currently under development or are already marketed. Based on the standard dosage regime and the likely injection frequency, shortlisting the highly likely candidates for delivery via bolus injectors. For these molecules under development, estimating the likely timeline by when they will be ready for subcutaneous administration. Estimating the proportion of these molecules which will be available for subcutaneous delivery via large volume wearable injectors for around 14 disease classes. Estimating the sales potential (both in terms of value and volume) of these injectors for each drug-disease combination over the next ten years. Where possible, we have added robustness to our forecasting model by conducting extensive primary research interviews with senior stakeholders in the industry. Owing to the uncertain nature of the market, we have provided three scenarios for our market forecast. The conservative, base and optimistic scenarios are considered for the forecasting of each of the analysed drug-disease combinations and represent three different tracks of industry evolution.

...read more
3D Bioprinting Market, 2014 - 2030

The 3D printing industry has come a long way over the last many years; the technology has the potential of revolutionising the way things occur currently. Many industries have already benefitted from multiple advancements in this field, resulting in improved and more efficient processes worldwide. A quick look at www.3dprintingchannel.com suggests that 3D printing has multi-faceted dimensions; the technology has recently been used in varied industries such as automotive, medical, business, industrial equipments, education, architecture, and consumer products. There is a widespread optimism that it is likely to gain prominence in the coming years and have a far reaching impact on our daily lives. Within healthcare, 3D printed prosthetics and implants have already been in the market for some years. Layerwise from Belgium and Xilloc from Netherlands are the major companies dealing with 3D printed medical and dental implants. Xilloc was in the news recently for creating the first customized 3D-printed lower jaw for an 83-year old patient with a serious jaw infection. Another company, Oxford Performance Materials, from USA, received FDA approval for a 3D printed implant that replaced 75% of a man’s skull. Specifically, 3D bioprinting is gradually emerging as an area which is garnering attention from a lot of academicians. Some of these researchers have also recently opened start-up firms with the aim of commercialising the technology over the next decade or so.   Scope of the Report The ‘3D Bioprinting, 2014 - 2030’ report provides an extensive study of the emerging market of 3D bioprinting, specifically focusing on commercial bioprinters and those under development, their applications and the likely future evolution. It is widely anticipated that the 3D bioprinting market has tremendous potential: it requires hardware (bioprinters), software (CAD), biocompatible materials (bio-ink and bio-paper), each of which has the capability to grow into separate niche industries. The report covers various aspects such as technological progress, product pipeline, industry and academic research programs and regulatory concerns to assess new evolving opportunities. One of the key objectives of this report is to understand the current and future state of the bioprinters and products derived thereof. This is done by analysing the following: Commercial 3D Bioprinters currently available in the market Innovations of academic groups across various research institutes across the globe Competing technologies with similar applications in the healthcare industry Size of target consumer segments The widening supply-demand gap, specifically for organ transplants. The base year for the report is 2014. The report provides short-mid term and long term market forecasts for the period 2014 - 2024 and 2024 - 2030, respectively. We have discussed, in detail, key drivers behind the likely growth of 3D bioprinting market. The research, analysis and insights presented in this report include the sales potential of various 3D bioprinted products based on the current expected market launch timelines, their adoption rates and the estimated end-use price points. The figures mentioned in this report are in USD, unless otherwise specified.

...read more
Bolus Injectors Market, 2014 - 2024

The injectable drug delivery market holds significant potential for the future. From the conventional syringes with vials and painful needles to the modern-day pre-filled syringes, pen-injectors, needle free injectors and auto-injectors, the injectable drug delivery devices market has come a long way. Taking the concept of self-injectors to a new stratum, ‘Bolus Injectors’ have surfaced recently. Also known as non-insulin patch pumps, these devices not only offer a range of benefits to the end users but also provide a number of additional benefits to other stakeholders in the industry. One of the main drivers for the perceived growth of bolus injectors is the large number of biologics currently under development. A majority of these molecules are highly viscous and are required to be delivered in volumes of greater than 1 ml. The absence of devices which can safely administer these drugs is currently a big unmet need in the market. However, the early signs are encouraging. Despite the uncertainties related to the device development and approval, many companies are investing time, money and resources to develop novel devices. This development is being led jointly by established firms such as Becton Dickinson, West Pharmaceuticals and emerging players such as Unilife, Ratio Drug Delivery and Sensile Medical, amongst others. It is widely anticipated that, once ready, such devices which will allow self-administration of high viscosity, large volume biologics and be readily adopted in the industry.   Scope of the Report The “Bolus Injectors” report provides a comprehensive analysis of the current state of this market and the likely future evolution over the next ten years. Starting with the basic introduction to bolus injectors, their components, the report explains the advantages, usage mechanism and the current status of development of each of these devices. As these injectors are currently only available for investigational use, the investment being done in this area is geared towards tapping the significant future potential of this market. In fact, one of the primary objectives of this report is to estimate the size of this future promise offered by bolus injectors. For the purposes of our analysis, we followed a top-down approach to estimate the size of this market. This included: Conducting an extensive research to identify high viscosity and large volume biologics which are either currently under development or have already been marketed. For the molecules under development, estimating the likely timeline by when they will be ready for intravenous infusion formulation. Estimating the likely proportion of these molecules which will be available for subcutaneous delivery via bolus injectors for 15 disease classes. Estimating the sales of bolus injectors (both in terms of unit sales and market value) for each drug-disease combination over the next ten years. Where possible, we have added robustness to our forecasting model by conducting extensive primary research interviews with senior stakeholders in the industry. Owing to the uncertain nature of the market, we provide three scenarios for our market forecast. The conservative, base and optimistic scenarios are considered for the forecasting of each of the analysed drug-disease combinations and represent three different tracks of industry evolution.

...read more

OUR CLIENTS

  • We are your partners with no equity

  • We fit in your budget

  • We love what we do

  • Chance to prove ourselves

  • Best in class quality of work

  • Most trusted consulting partner in the industry